{
  "ticker": "LLY",
  "target_date": "2025-11-11",
  "actual_date": "2025-11-11",
  "collected_at": "2025-12-08T12:31:12.579179",
  "price": {
    "open": 965.13,
    "high": 998.48,
    "low": 963.87,
    "close": 987.1702270507812,
    "volume": 4166400,
    "change_1d_pct": 2.27,
    "change_7d_pct": 14.57,
    "change_30d_pct": 29.57
  },
  "technicals": {
    "rsi_14": 88.62,
    "sma_20": 860.23,
    "sma_50": 808.69,
    "macd": 43.52,
    "macd_signal": 31.094,
    "macd_histogram": 12.426,
    "bb_upper": 979.94,
    "bb_lower": 740.52,
    "price_vs_sma20_pct": 14.76,
    "price_vs_sma50_pct": 22.07,
    "volume_ratio": 1.05
  },
  "fundamentals": {
    "market_cap": 892959588352,
    "pe_ratio": 48.804455,
    "forward_pe": 43.95847,
    "price_to_book": 37.503723,
    "price_to_sales": 15.027981,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.42,
    "pct_from_52w_low": 59.69
  },
  "macro": {
    "spy": {
      "price": 683.0,
      "change_1d_pct": 0.23,
      "change_7d_pct": -0.05
    },
    "vix": {
      "level": 17.28,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.12
    },
    "dollar_index": {
      "level": 99.46
    },
    "gold": {
      "price": 4106.8
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Jim Cramer on Eli Lilly: \u201cWe\u2019re Not a Seller\u201d",
      "source": "Yahoo",
      "datetime": 1762889693,
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer offered insights on. Cramer discussed the future possibilities of the company\u2019s weight loss drug, as he said: \u201c\u2026 Eli Lilly, which I think has beaten back Danish Novo Nordisk, maybe even into submission. After all, Lilly\u2019s on the market",
      "url": "https://finnhub.io/api/news?id=034c16fa06f49f58afbf90cbac9d2a2bbeeff8f9a0eb9db75d7b2db7c060da3b"
    },
    {
      "headline": "Jim Cramer Says \u201cI Think Pfizer\u2019s Very Smart to Buy Metsera\u201d",
      "source": "Yahoo",
      "datetime": 1762889692,
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer offered insights on. Cramer discussed the company\u2019s acquisition of Metsera during the episode. He commented: \u201cThere\u2019s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be bigger th",
      "url": "https://finnhub.io/api/news?id=282d1f835c49c4d23e3d28fae8d1a7131c6e34926f05875b7d096b3f0b4371e8"
    },
    {
      "headline": "European Equities Rise Sharply Again in Tuesday Trading; Novo Nordisk Slashes Wegovy Prices in India to Compete With Eli Lilly",
      "source": "Yahoo",
      "datetime": 1762881094,
      "summary": "The European stock markets closed sharply higher for the second straight session in Tuesday trading",
      "url": "https://finnhub.io/api/news?id=92eb8a787253ac0a0f31350f8b718eb206d4afc15b280ab23aef45de650ee7e3"
    },
    {
      "headline": "Why cutting drug prices is pushing Eli Lilly\u2019s stock to all-time highs",
      "source": "MarketWatch",
      "datetime": 1762880700,
      "summary": "Why cutting drug prices is pushing Eli Lilly\u2019s stock to all-time highs",
      "url": "https://finnhub.io/api/news?id=ad8ddc39102975936469082ec98edfa356e2438e66bc5c43f7d3992d814ad970"
    },
    {
      "headline": "Eli Lilly stock soars to new highs, Novo Nordisk lags. Here's why.",
      "source": "Yahoo",
      "datetime": 1762878712,
      "summary": "Eli Lilly (LLY) stock is trading at record highs after the pharmaceutical company reached a deal with the White House to offer weight-loss drugs at a discount. Novo Nordisk (NVO), which was also part of Trump's GLP-1 deal, has not seen its stock climb to fresh record highs on the agreement. BMO Capi",
      "url": "https://finnhub.io/api/news?id=067d9ad18f44dc2705b14eb49b0df4b2bcc76f65368ac04f7798f9d9124a006e"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-11-10",
      "description": "xslF345X05/wk-form4_1762815690.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000153860425000006/xslF345X05/wk-form4_1762815690.xml"
    },
    {
      "form": "4",
      "date": "2025-11-10",
      "description": "xslF345X05/wk-form4_1762815639.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000174147425000006/xslF345X05/wk-form4_1762815639.xml"
    },
    {
      "form": "4",
      "date": "2025-11-06",
      "description": "xslF345X05/form4-11062025_041104.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000055/xslF345X05/form4-11062025_041104.xml"
    },
    {
      "form": "4",
      "date": "2025-11-06",
      "description": "xslF345X05/form4-11062025_041102.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000054/xslF345X05/form4-11062025_041102.xml"
    },
    {
      "form": "4",
      "date": "2025-11-05",
      "description": "xslF345X05/form4-11052025_041101.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000051/xslF345X05/form4-11052025_041101.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}